Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRXX-Combinatorx -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (79)	12/2/2008 11:33:42 AM
From: dr.praveen	Respond to of 100

I agree. whats amazing to me is the no of experts backing the concept and the company

To: tuck who wrote (79)	12/2/2008 11:34:15 AM
From: mopgcw	Respond to of 100

i think the term was greenmail back in the day.. ...ITEM 4. Purpose of Transaction The Reporting Persons met with the Chief Executive Officer of the Issuer on October 29, 2008. During this meeting the Reporting Persons stated that, in their opinion, the Issuer should, as a first step, immediately downsize in order to preserve capital. On November 4, the Issuer announced such a downsizing. On November 5, 2008, the Issuer stated that it had cash, cash equivalents, restricted cash and short-term investments of $69.5 million, or $1.99/share, as of September 30, 2008, and expects to have $56.0-$62.0 million, or $1.60 - $1.78/share, at year end 2008. Further, the Issuer stated that its remaining cash will "carry the company into 2011". The Reporting Persons believe spending the Issuer's remaining cash on the development of its early-stage drug candidates, technology platform, and general corporate infrastructure is fundamentally flawed, especially in light of the current environment for raising additional capital. The Reporting Persons believe that the company’s drug candidates are all high risk and are best developed (if at all) by larger companies with greater financial resources and a lower cost of capital. By the time any of the company's products could be commercialized, or even definitively proven safe and efficacious, the Issuer's existing cash resources would be depleted. The Reporting Persons believe that the investment community clearly lacks confidence in such a plan, as evidenced by the $0.61 per share closing price of the Issuer's common stock on November 6, 2008, reflecting only 31% of the company’s cash, cash equivalents, restricted cash and short-term investments as of September 30, 2008. In lieu of the Issuer’s articulated plan, the Reporting Persons believe the Issuer should implement one of the following two plans: 1. Return as much capital as possible to shareholders as soon as practical. This would require an immediate further downsizing of the Issuer to a minimal possible level and monetizing its remaining drug candidates and other assets. OR 2. Committing now to a cash tender of any and all shares of common stock at a fixed price on a preset future date. (e.g., $1.00/share on June 1, 2009). This would protect the downside risk of all shareholders while enabling the Issuer to continue to pursue its current business plan, if it so chooses. If the Issuer is successful in executing its plan, and thereby "beating the tender", most shareholders will likely choose not to tender their shares and, accordingly, the Issuer would retain the corresponding tender proceeds. The Reporting Persons look forward to continuing to work with the Issuer to effectuate one of these plans. ITEM 5. Interest in Securities of the Issuer...

To: tuck who wrote (79)	12/2/2008 2:48:40 PM
From: rkrw	Respond to of 100

My guess is bvf and crxx will settle and perhaps a special dividend will be paid. imo the company is a complete fraud and bvf is right, the decent and best thing to do would be to liquidate. I don't think bvf is continuing to buy because they want to stick around for the next 4 years as cash drains to zero. Clearly there must be no poison pill in place, so maybe bvf is aiming to own 50.1%.

To: tuck who wrote (79)	12/10/2008 10:08:47 PM
From: rkrw	Respond to of 100

Just a thought, crxx ceo claims their screening system spits out random synergistic combinations. This one doesn't sound so random.....as in did it really come from their platform?..... <<Prednisolone is a well-known corticosteroid which is used to suppress inflammation and the immunen response. Dipyridamole is a multi-mechanism drug that increases the free concentration of adenosine, and it's been used to inhibit clotting and lower pulmonary hypertension. Blood pressure problems are common with prednisolone, and the company believed that the prednisolone dose could be taken down to non-side-effect levels in the presence of the other drug.>>>